In summary, we provide for the first time clinical and functional evidence that the described putative tumor suppressive function of NDRG2 may be confined to luminal-type and basal B-type (more reflecting mesenchymal TNBC) breast cancers. The gene discussed is NDRG2; the disease is neoplasm.